Brokerages Anticipate Pacira Pharmaceuticals, Inc. (PCRX) to Announce $0.12 Earnings Per Share

Analysts expect that Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) will announce $0.12 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Pacira Pharmaceuticals’ earnings, with estimates ranging from ($0.10) to $0.25. Pacira Pharmaceuticals posted earnings per share of $0.09 in the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The business is expected to report its next earnings results on Wednesday, March 7th.

According to Zacks, analysts expect that Pacira Pharmaceuticals will report full year earnings of ($0.06) per share for the current fiscal year, with EPS estimates ranging from ($0.29) to $0.09. For the next year, analysts forecast that the company will post earnings of $0.65 per share, with EPS estimates ranging from ($0.47) to $1.56. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow Pacira Pharmaceuticals.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.15. The company had revenue of $67.30 million for the quarter, compared to analysts’ expectations of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The firm’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.20 earnings per share.

A number of brokerages have weighed in on PCRX. Janney Montgomery Scott raised shares of Pacira Pharmaceuticals from a “sell” rating to a “neutral” rating and set a $31.00 target price on the stock in a report on Monday, August 21st. Royal Bank Of Canada reissued an “outperform” rating and set a $54.00 target price on shares of Pacira Pharmaceuticals in a report on Tuesday, September 5th. Oppenheimer began coverage on shares of Pacira Pharmaceuticals in a report on Thursday, September 7th. They set a “market perform” rating on the stock. UBS began coverage on shares of Pacira Pharmaceuticals in a report on Wednesday, September 6th. They set a “market perform” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $52.00 target price on shares of Pacira Pharmaceuticals in a report on Thursday, November 9th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $48.86.

Shares of Pacira Pharmaceuticals (PCRX) traded up $0.60 during trading hours on Friday, hitting $44.80. 744,557 shares of the company’s stock were exchanged, compared to its average volume of 755,937. Pacira Pharmaceuticals has a 52 week low of $29.81 and a 52 week high of $58.95. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99.

In related news, CEO David M. Stack sold 58,885 shares of the stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $38.34, for a total value of $2,257,650.90. Following the completion of the transaction, the chief executive officer now owns 159,164 shares in the company, valued at approximately $6,102,347.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Kristen Marie Williams sold 10,000 shares of the stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the transaction, the chief accounting officer now owns 23,455 shares of the company’s stock, valued at approximately $938,200. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,735 shares of company stock worth $2,692,594. Corporate insiders own 6.60% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. grew its position in Pacira Pharmaceuticals by 5.2% in the 2nd quarter. Principal Financial Group Inc. now owns 5,466 shares of the company’s stock valued at $261,000 after buying an additional 270 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in Pacira Pharmaceuticals by 9.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after buying an additional 302 shares in the last quarter. Denver Investment Advisors LLC grew its position in Pacira Pharmaceuticals by 6.8% in the 2nd quarter. Denver Investment Advisors LLC now owns 6,850 shares of the company’s stock valued at $327,000 after buying an additional 435 shares in the last quarter. Amalgamated Bank grew its position in Pacira Pharmaceuticals by 12.7% in the 2nd quarter. Amalgamated Bank now owns 5,030 shares of the company’s stock valued at $240,000 after buying an additional 566 shares in the last quarter. Finally, Legal & General Group Plc grew its position in Pacira Pharmaceuticals by 5.3% in the 2nd quarter. Legal & General Group Plc now owns 12,985 shares of the company’s stock valued at $620,000 after buying an additional 653 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/10/brokerages-anticipate-pacira-pharmaceuticals-inc-pcrx-to-announce-0-12-earnings-per-share.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply